Literature DB >> 3967252

Methodologic guidelines for reports of clinical trials.

R Simon, R E Wittes.   

Abstract

Mesh：

Year:  1985        PMID： 3967252

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  21 in total

1.  Clinical trials in urogynecology.

Authors:  D Moher
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1997

2.  Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  David O Walterhouse; Alberto S Pappo; Jane L Meza; John C Breneman; Andrea A Hayes-Jordan; David M Parham; Timothy P Cripe; James R Anderson; William H Meyer; Douglas S Hawkins
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

3.  Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso.

Authors:  Patricia J Hollen; Richard J Gralla; Astra M Liepa; James T Symanowski; James J Rusthoven
Journal:  Support Care Cancer       Date:  2005-07-06       Impact factor: 3.603

4.  Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  David O Walterhouse; Alberto S Pappo; Jane L Meza; John C Breneman; Andrea Hayes-Jordan; David M Parham; Timothy P Cripe; James R Anderson; William H Meyer; Douglas S Hawkins
Journal:  Cancer       Date:  2017-02-17       Impact factor: 6.860

5.  Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy.

Authors:  T Hattori; T Nakajima; H Nakazato; T Tanabe; K Kikuchi; O Abe; T Kondo; T Taguchi; N Komi; K Sugimachi
Journal:  Jpn J Surg       Date:  1990-03

6.  Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  R Beverly Raney; David O Walterhouse; Jane L Meza; Richard J Andrassy; John C Breneman; William M Crist; Harold M Maurer; William H Meyer; David M Parham; James R Anderson
Journal:  J Clin Oncol       Date:  2011-02-28       Impact factor: 44.544

7.  Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.

Authors:  David O Walterhouse; Jane L Meza; John C Breneman; Sarah S Donaldson; Andrea Hayes-Jordan; Alberto S Pappo; Carola Arndt; R Beverly Raney; William H Meyer; Douglas S Hawkins
Journal:  Pediatr Blood Cancer       Date:  2011-02-04       Impact factor: 3.167

8.  The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group.

Authors:  R Sposto; I J Ertel; R D Jenkin; C P Boesel; J L Venes; J A Ortega; A E Evans; W Wara; D Hammond
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

9.  Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer.

Authors:  Patricia J Hollen; Richard J Gralla; Cynthia N Rittenberg
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

Review 10.  Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.

Authors:  Anastasia Ivanova; Barry Paul; Olga Marchenko; Guochen Song; Neerali Patel; Stergios J Moschos
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.